Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b PIPAC in unresectable peritoneal carcinomatosis
2021-001417-36Phase 2Active
- Sponsor
- Hospital Clínico Universitario
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, doxorubicin and oxaliplatin in peritoneal carcinomatosis (PC), sponsored by Hospital Clínico Universitario. Primary endpoint: Histological tumor regression by PGRS. Started Jun 2021; status: active.
02
Drugs
cisplatindoxorubicinoxaliplatin
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on 2021-001417-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001417-36.